Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Trial of Doxorubicin and Paclitaxel Sequence in Locally Advanced Breast Cancer
NCT00003035Phase 2
Key facts
- Status
- Completed
- Start
- Mar 1997
- Primary completion
- Jun 2001
- Countries
- 1
- Sponsor
- Georgetown University
- Modality
- DNA Intercalators/Alkylators
- Conditions
- breast cancer
01
Overview
Phase 2, randomised, open-label trial of doxorubicin and paclitaxel in breast cancer (2 arms), sponsored by Georgetown University. Primary endpoints: Feasibility of obtaining serial biopsies and Feasibility of performing assays of apoptosis. Started Mar 1997; status: completed.
02
Design
2 arms- Study design
- RandomizedOpen-label
Doxorubicin -> Paclitaxel
Doxorubicin followed by Paclitaxel
Paclitaxel -> Doxorubicin
Paclitaxel followed by Doxorubicin
03
Who it enrols
Women with histologically proven locally advanced breast cancer (unresected T3 or T4, or T2 if candidate for neoadjuvant). Patients must have adequate bone marrow, hepatic, renal, and cardiac function.
04
Endpoints
Primary
Feasibility of obtaining serial biopsies
Feasibility of performing assays of apoptosis
Secondary
Clinical Response Rate
Pathologic Response Rate
Beyond the preview
Go deeper on NCT00003035.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003035.